APGE logo

APGE
Apogee Therapeutics

441
Mkt Cap
$6.13B
Volume
105,444.00
52W High
$95.32
52W Low
$34.34
PE Ratio
-19.05
APGE Fundamentals
Price
$82.12
Prev Close
$82.43
Open
$83.15
50D MA
$81.88
Beta
0.00
Avg. Volume
649,714.20
EPS (Annual)
-$4.22
P/B
4.92
Rev/Employee
$0.00
$3,859.60
Loading...
Loading...
News
all
press releases
Apogee Therapeutics (APGE) to Release Earnings on Monday
Apogee Therapeutics (NASDAQ:APGE) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-apogee-therapeutics-inc-stock...
News Placeholder
More News
News Placeholder
Apogee Therapeutics (NASDAQ:APGE) Upgraded to Strong-Buy at Rothschild & Co Redburn
Rothschild & Co Redburn upgraded Apogee Therapeutics to a "strong-buy" rating in a research report on Friday...
News Placeholder
Jennison Associates LLC Invests $43.68 Million in Apogee Therapeutics Inc. $APGE
Jennison Associates LLC purchased a new position in shares of Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 578,627 shares of the company's stock, val...
News Placeholder
Pictet Asset Management Holding SA Takes $23.62 Million Position in Apogee Therapeutics Inc. $APGE
Pictet Asset Management Holding SA bought a new stake in shares of Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) during the 4th quarter, according to its most recent filing with the Securities...
News Placeholder
Apogee Therapeutics (NASDAQ:APGE) Reaches New 1-Year High - Still a Buy?
Apogee Therapeutics (NASDAQ:APGE) Reaches New 52-Week High - Time to Buy...
News Placeholder
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seventeen brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recomme...
News Placeholder
Insider Selling: Apogee Therapeutics (NASDAQ:APGE) CEO Sells 20,000 Shares of Stock
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) CEO Michael Thomas Henderson sold 20,000 shares of the firm's stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $82.58, for a total transaction of $1,651,600.00. Following the completion of the...
News Placeholder
Aberdeen Group plc Lowers Stake in Apogee Therapeutics Inc. $APGE
Aberdeen Group plc lessened its stake in Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) by 34.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional...
News Placeholder
Apogee Therapeutics (NASDAQ:APGE) Hits New 12-Month High - Still a Buy?
Apogee Therapeutics (NASDAQ:APGE) Reaches New 12-Month High - Should You Buy...
News Placeholder
Apogee Therapeutics (NASDAQ:APGE) Insider Sells $466,620.00 in Stock
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 5,500 shares of the firm's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available